Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies
Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid...
Saved in:
| Published in | Brain (London, England : 1878) Vol. 135; no. 6; pp. 1900 - 1913 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Oxford University Press
01.06.2012
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson's disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects-108 synucleinopathy patients (34 Parkinson's disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 ± 0.09 (SEM), 1.00 ± 0.09, 1.32 ± 0.12 nmol/l] than controls (2.15 ± 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 ± 0.44, 7.75 ± 0.42, 5.82 ± 0.65 nmol/l) than controls (11.0 ± 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson's disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson's disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson's disease. |
|---|---|
| AbstractList | Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson's disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects-108 synucleinopathy patients (34 Parkinson's disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 ± 0.09 (SEM), 1.00 ± 0.09, 1.32 ± 0.12 nmol/l] than controls (2.15 ± 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 ± 0.44, 7.75 ± 0.42, 5.82 ± 0.65 nmol/l) than controls (11.0 ± 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson's disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson's disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson's disease.Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson's disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects-108 synucleinopathy patients (34 Parkinson's disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 ± 0.09 (SEM), 1.00 ± 0.09, 1.32 ± 0.12 nmol/l] than controls (2.15 ± 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 ± 0.44, 7.75 ± 0.42, 5.82 ± 0.65 nmol/l) than controls (11.0 ± 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson's disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson's disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson's disease. Central catecholamine deficiency characterizes alpha -synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson's disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects-108 synucleinopathy patients (34 Parkinson's disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 plus or minus 0.09 (SEM), 1.00 plus or minus 0.09, 1.32 plus or minus 0.12 nmol/l] than controls (2.15 plus or minus 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 plus or minus 0.44, 7.75 plus or minus 0.42, 5.82 plus or minus 0.65 nmol/l) than controls (11.0 plus or minus 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson's disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson's disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson's disease. Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson's disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects-108 synucleinopathy patients (34 Parkinson's disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 ± 0.09 (SEM), 1.00 ± 0.09, 1.32 ± 0.12 nmol/l] than controls (2.15 ± 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 ± 0.44, 7.75 ± 0.42, 5.82 ± 0.65 nmol/l) than controls (11.0 ± 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson's disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson's disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson's disease. Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson’s disease. We hypothesized that cerebrospinal fluid levels of neuronal metabolites of catecholamines provide neurochemical biomarkers of these disorders. To test this hypothesis we measured cerebrospinal fluid levels of catechols including dopamine, norepinephrine and their main respective neuronal metabolites dihydroxyphenylacetic acid and dihydroxyphenylglycol in Parkinson’s disease and two other synucleinopathies, multiple system atrophy and pure autonomic failure. Cerebrospinal fluid catechols were assayed in 146 subjects—108 synucleinopathy patients (34 Parkinson’s disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls. In 14 patients cerebrospinal fluid was obtained before or within 2 years after the onset of parkinsonism. The Parkinson’s disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal fluid dihydroxyphenylacetic acid [0.86 ± 0.09 (SEM), 1.00 ± 0.09, 1.32 ± 0.12 nmol/l] than controls (2.15 ± 0.18 nmol/l; P < 0.0001; P < 0.0001; P = 0.0002). Dihydroxyphenylglycol was also lower in the three synucleinopathies (8.82 ± 0.44, 7.75 ± 0.42, 5.82 ± 0.65 nmol/l) than controls (11.0 ± 0.62 nmol/l; P = 0.009, P < 0.0001, P < 0.0001). Dihydroxyphenylacetic acid was lower and dihydroxyphenylglycol higher in Parkinson’s disease than in pure autonomic failure. Dihydroxyphenylacetic acid was 100% sensitive at 89% specificity in separating patients with recent onset of parkinsonism from controls but was of no value in differentiating Parkinson’s disease from multiple system atrophy. Synucleinopathies feature cerebrospinal fluid neurochemical evidence for central dopamine and norepinephrine deficiency. Parkinson’s disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions. Cerebrospinal fluid dihydroxyphenylacetic acid seems to provide a sensitive means to identify even early Parkinson’s disease. |
| Author | Goldstein, David S. Sharabi, Yehonatan Holmes, Courtney |
| AuthorAffiliation | Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1620, USA |
| AuthorAffiliation_xml | – name: Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1620, USA |
| Author_xml | – sequence: 1 givenname: David S. surname: Goldstein fullname: Goldstein, David S. – sequence: 2 givenname: Courtney surname: Holmes fullname: Holmes, Courtney – sequence: 3 givenname: Yehonatan surname: Sharabi fullname: Sharabi, Yehonatan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25912266$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22451506$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFksuKFDEUhoOMOD2jO9eSjeDCcnKppCobYWi8wYAudB1SySn7aHXSJtUOvfM1fD2fxLTd4w3BVQjnO3_On_OfkZOYIhByn7MnnBl5MWSH8cJdF6bULbLgrWaN4EqfkAVjTDe9UeyUnJXygTHeSqHvkFMhWsUV0wtyvYQMQ05lg9FNdJy2GOiAae3yR8iFppF6iHOuNe9m8Ks0uTVGoAFG9AjR7yhG-qbiGEuK3758LTRgAVeAuhhomleQadnFrZ8AY9q4eYVQ7pLbo5sK3Due5-Td82dvly-bq9cvXi0vrxqvuJwbE2QrOJheDqzr5BACU30fOjVI3Y4Chr7enBGhd0KxthsNC51uW-iUkl3Q8pw8PehutsMawtGL3WSsDnc2ObR_ViKu7Pv02UqpTNeaKvDoKJDTpy2U2a6xeJgmFyFti61f2jKujZH_RyunOy25quiD38f6Oc_NYirw8Ai44t00Zhc9ll-cMlwIvefEgfN1hyXDaD3Obsa0d4NTfdPuU2J_pMQeUlKbHv_VdKP7T_w7iUvEDg |
| CitedBy_id | crossref_primary_10_32607_actanaturae_27511 crossref_primary_10_3390_metabo11120860 crossref_primary_10_1016_j_parkreldis_2014_04_003 crossref_primary_10_3389_fcell_2022_1030390 crossref_primary_10_1080_10408363_2024_2331471 crossref_primary_10_1093_braincomms_fcab116 crossref_primary_10_1212_WNL_0000000000003737 crossref_primary_10_1016_j_mayocp_2019_03_009 crossref_primary_10_1038_nrneurol_2014_232 crossref_primary_10_1111_jnc_15371 crossref_primary_10_1111_jnc_13997 crossref_primary_10_1038_srep44872 crossref_primary_10_1007_s11064_020_03002_5 crossref_primary_10_1002_mds_25202 crossref_primary_10_1016_j_neuint_2013_06_005 crossref_primary_10_3390_ijms23031879 crossref_primary_10_1161_HYPERTENSIONAHA_114_04225 crossref_primary_10_1016_j_pharmthera_2014_06_006 crossref_primary_10_1002_mds_25555 crossref_primary_10_1016_j_apsusc_2020_146466 crossref_primary_10_2478_s13380_012_0013_1 crossref_primary_10_1007_s00702_019_02001_3 crossref_primary_10_1016_j_bios_2021_113351 crossref_primary_10_1002_mds_28786 crossref_primary_10_1186_s12866_024_03373_7 crossref_primary_10_1177_1179573518803585 crossref_primary_10_1021_acschemneuro_3c00611 crossref_primary_10_1080_00222895_2014_941784 crossref_primary_10_1080_14737175_2021_1953984 crossref_primary_10_3390_chemosensors13030087 crossref_primary_10_3389_fnins_2018_00626 crossref_primary_10_1016_j_nbd_2015_05_004 crossref_primary_10_1016_j_mad_2023_111875 crossref_primary_10_1007_s10286_015_0302_1 crossref_primary_10_7554_eLife_52904 crossref_primary_10_1016_j_trac_2024_117873 crossref_primary_10_1093_brain_awad260 crossref_primary_10_1111_ane_12590 crossref_primary_10_1039_D1NR03691B crossref_primary_10_1080_14737175_2017_1392239 crossref_primary_10_1002_adfm_202002141 crossref_primary_10_1080_10408363_2017_1299682 crossref_primary_10_1002_mds_28608 crossref_primary_10_1021_acs_analchem_3c02900 crossref_primary_10_1038_s41598_022_10528_x crossref_primary_10_1136_jnnp_2013_307539 crossref_primary_10_1007_s10286_023_00987_1 crossref_primary_10_1021_acs_analchem_0c02667 crossref_primary_10_1093_brain_awab111 crossref_primary_10_1097_WNN_0000000000000198 crossref_primary_10_1016_j_bioelechem_2022_108148 crossref_primary_10_1038_s41467_024_45107_3 crossref_primary_10_3390_brainsci14020156 crossref_primary_10_1161_HYPERTENSIONAHA_118_12642 crossref_primary_10_1039_D2NR07157F crossref_primary_10_1124_jpet_115_230201 crossref_primary_10_3390_diagnostics10050339 crossref_primary_10_1007_s11302_018_9643_2 crossref_primary_10_1002_pssa_201900924 crossref_primary_10_3389_fphar_2020_00435 crossref_primary_10_1002_aisy_202300227 crossref_primary_10_1016_j_jchromb_2018_01_025 crossref_primary_10_3233_JPD_212936 crossref_primary_10_1016_j_saa_2022_122303 crossref_primary_10_1002_elsa_202000026 crossref_primary_10_1007_s11306_021_01866_4 crossref_primary_10_1111_jnc_12345 crossref_primary_10_3390_bios11110433 crossref_primary_10_1016_j_parkreldis_2019_09_014 crossref_primary_10_3390_separations8080124 crossref_primary_10_1093_toxsci_kfx028 crossref_primary_10_1016_j_parkreldis_2015_03_006 crossref_primary_10_3892_etm_2021_10443 crossref_primary_10_1016_j_neuint_2017_01_007 crossref_primary_10_1016_j_parkreldis_2018_02_023 crossref_primary_10_18786_2072_0505_2018_46_8_792_801 crossref_primary_10_1186_s12951_022_01695_0 crossref_primary_10_3390_brainsci10070466 crossref_primary_10_1016_j_parkreldis_2016_07_009 crossref_primary_10_1002_ana_26089 crossref_primary_10_3389_fneur_2020_00595 crossref_primary_10_1002_mds_26048 crossref_primary_10_3233_JPD_160867 crossref_primary_10_1186_s13024_018_0304_2 crossref_primary_10_1021_acs_analchem_3c00113 crossref_primary_10_1111_jnc_16168 crossref_primary_10_1039_D3AN00027C crossref_primary_10_1186_s40673_014_0014_7 crossref_primary_10_1007_s00604_021_04945_4 crossref_primary_10_3390_ijms252111406 crossref_primary_10_1016_j_jcis_2012_12_073 crossref_primary_10_1111_cns_13429 crossref_primary_10_1016_j_neuint_2019_104514 crossref_primary_10_1002_iub_1718 crossref_primary_10_1007_s12035_018_1315_2 crossref_primary_10_3390_cells9112394 crossref_primary_10_1097_OPX_0000000000002168 crossref_primary_10_3390_metabo11040233 |
| Cites_doi | 10.1016/0022-510X(93)90316-Q 10.1016/S1474-4422(11)70014-X 10.1309/W01Y0B808EMEH12L 10.1016/j.nbd.2003.09.001 10.1016/S0304-3940(00)01623-2 10.1002/ana.410270405 10.1212/WNL.42.11.2111 10.1017/S0317167100031814 10.1093/clinchem/32.11.2030 10.1126/science.276.5321.2045 10.1016/0160-5402(82)90073-0 10.1212/WNL.0b013e3181d26982 10.1111/j.1600-0773.1984.tb01967.x 10.1007/BF01271258 10.1021/tx800405v 10.1007/s10286-008-0457-0 10.1001/archneur.1984.04210080020007 10.1016/j.parkreldis.2011.04.016 10.1007/BF02252962 10.1001/archneur.65.8.1074 10.1002/mds.10557 10.1016/S0006-3223(99)00008-6 10.1126/science.129.3357.1226 10.1016/S0304-3940(98)00407-8 10.1111/j.1469-1809.2009.00560.x 10.1097/00004647-200202000-00011 10.1016/0378-4347(93)E0430-X 10.1007/BF01485901 10.1172/JCI45803 10.1016/S0022-3565(25)11162-2 10.2967/jnumed.108.061572 10.1111/j.2042-7158.1987.tb06973.x 10.1212/WNL.57.6.1140 10.1176/jnp.2.1.114 10.1111/j.1471-4159.1992.tb10977.x 10.1042/CS20020315 10.1001/archneur.60.3.337 10.1007/s10286-006-0317-8 10.1016/S0022-3565(25)30363-0 10.1196/annals.1344.031 10.1212/WNL.43.5.986 10.3949/ccjm.74.Suppl_1.S91 10.1023/A:1024255208563 10.1038/jcbfm.1993.8 10.1212/WNL.0b013e3181cff6d5 10.1016/S1474-4422(03)00555-6 10.1096/fj.03-1449com 10.1016/j.neuro.2006.07.018 10.1007/s00441-004-0956-9 10.1093/brain/awm302 10.1136/jnnp.73.6.776 10.1212/WNL.58.8.1247 10.1056/NEJM197702102960601 10.1038/42166 10.1186/1477-5956-6-8 10.1111/j.1600-0404.1995.tb01023.x 10.1007/BF01252815 10.1111/j.1750-3639.1999.tb00553.x 10.1124/pr.56.3.1 10.1093/brain/120.12.2187 10.1210/jcem-64-4-856 10.1007/s00401-006-0160-y 10.1002/ana.22311 10.1007/BF02291236 10.1001/jama.1971.03190260019005 10.1002/ana.410260410 10.1016/0006-3223(86)90328-8 10.1016/j.parkreldis.2008.01.010 10.1111/j.1468-1331.2010.03246.x |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Published by Oxford University Press on behalf of the Guarantors of Brain 2012. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2012 |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Published by Oxford University Press on behalf of the Guarantors of Brain 2012. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2012 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7TK 5PM |
| DOI | 10.1093/brain/aws055 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | MEDLINE - Academic Neurosciences Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| EndPage | 1913 |
| ExternalDocumentID | PMC3359749 22451506 25912266 10_1093_brain_aws055 |
| Genre | Journal Article Research Support, N.I.H., Intramural |
| GrantInformation_xml | – fundername: PHS HHS grantid: 1ZIANS003034-05 – fundername: Intramural NIH HHS |
| GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 0R~ 1CY 1TH 23N 2WC 354 3O- 4.4 41~ 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAGKA AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT AAWTL AAYJJ AAYXX ABDFA ABDPE ABEJV ABEUO ABGNP ABIME ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNGD ABNHQ ABNKS ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACBNA ACFRR ACGFS ACIWK ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIJHB AJBYB AJDVS AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CITATION COF CS3 CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MBLQV MBTAY MHKGH ML0 MVM N4W N9A NGC NLBLG NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OBOKY OCZFY ODMLO OHH OHT OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCN TCURE TEORI TJX TLC TMA TR2 VH1 VVN W8F WH7 WOQ X7H X7M XJT XOL YAYTL YKOAZ YQJ YSK YXANX ZCG ZGI ZKB ZKX ZXP ~91 IQODW 6.Y ABQTQ ABSAR ADJQC ADRIX AFXEN CGR CUY CVF ECM EIF M49 NPM VXZ 7X8 7TK 5PM |
| ID | FETCH-LOGICAL-c513t-9d3421e983b0773bdd0588d75b364f2eb888da92d8a25047f90d7644e75537d63 |
| ISSN | 0006-8950 1460-2156 |
| IngestDate | Thu Aug 21 14:30:04 EDT 2025 Fri Jul 11 01:07:05 EDT 2025 Fri Jul 11 16:06:13 EDT 2025 Wed Feb 19 02:42:01 EST 2025 Mon Jul 21 09:12:59 EDT 2025 Tue Jul 01 05:17:58 EDT 2025 Thu Apr 24 23:01:08 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Parkinson's Nervous system diseases Dopamine DOPAC Deficiency Parkinson disease Cerebrospinal fluid Catecholamine biomarker Cerebral disorder Central nervous system disease Neurotransmitter Degenerative disease Norepinephrine DHPG Extrapyramidal syndrome |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c513t-9d3421e983b0773bdd0588d75b364f2eb888da92d8a25047f90d7644e75537d63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://academic.oup.com/brain/article-pdf/135/6/1900/13796907/aws055.pdf |
| PMID | 22451506 |
| PQID | 1016676315 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3359749 proquest_miscellaneous_1434016993 proquest_miscellaneous_1016676315 pubmed_primary_22451506 pascalfrancis_primary_25912266 crossref_citationtrail_10_1093_brain_aws055 crossref_primary_10_1093_brain_aws055 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-06-01 |
| PublicationDateYYYYMMDD | 2012-06-01 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2012 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Lloyd ( key 20170425181757_aws055-B45) 1975; 195 Emanuelsson ( key 20170425181757_aws055-B16) 1987; 39 Antonini ( key 20170425181757_aws055-B1) 1997; 120 Cotzias ( key 20170425181757_aws055-B7) 1971; 218 Chia ( key 20170425181757_aws055-B6) 1993; 116 Goldstein ( key 20170425181757_aws055-B24) 2003; 104 Mollenhauer ( key 20170425181757_aws055-B48) 2011; 10 LeWitt ( key 20170425181757_aws055-B44) 1992; 42 Braak ( key 20170425181757_aws055-B4) 2004; 318 Jokinen ( key 20170425181757_aws055-B37) 2009; 50 Galter ( key 20170425181757_aws055-B20) 2003; 14 Kaufmann ( key 20170425181757_aws055-B39) 1996; 6 Kvetnansky ( key 20170425181757_aws055-B42) 1992; 261 Eisenhofer ( key 20170425181757_aws055-B13) 2004; 56 Dickson ( key 20170425181757_aws055-B9) 1999; 9 Jinsmaa ( key 20170425181757_aws055-B36) 2009; 22 Scheinin ( key 20170425181757_aws055-B57) 1984; 55 Goldstein ( key 20170425181757_aws055-B23) 2011; 121 Rajput ( key 20170425181757_aws055-B55) 1991; 18 Goldstein ( key 20170425181757_aws055-B26) 2011; 18 Hoshi ( key 20170425181757_aws055-B34) 1993; 13 Edwards ( key 20170425181757_aws055-B10) 2010; 74 Goldstein ( key 20170425181757_aws055-B22) 2002; 58 DelleDonne ( key 20170425181757_aws055-B8) 2008; 65 Goldstein ( key 20170425181757_aws055-B30) 2006; 16 Sossi ( key 20170425181757_aws055-B60) 2002; 22 Goldstein ( key 20170425181757_aws055-B27) 1987; 64 Kuhn ( key 20170425181757_aws055-B41) 1996; 103 Palfreyman ( key 20170425181757_aws055-B53) 1982; 8 Holmes ( key 20170425181757_aws055-B33) 1994; 653 Polymeropoulos ( key 20170425181757_aws055-B54) 1997; 276 Goldstein ( key 20170425181757_aws055-B28) 2007; 74 Halliday ( key 20170425181757_aws055-B32) 1990; 27 Weil-Malherbe ( key 20170425181757_aws055-B64) 1959; 129 Orimo ( key 20170425181757_aws055-B52) 2008; 131 Engelborghs ( key 20170425181757_aws055-B17) 2003; 28 Jellinger ( key 20170425181757_aws055-B35) 2003; 18 Kish ( key 20170425181757_aws055-B40) 1984; 41 Goldstein ( key 20170425181757_aws055-B21) 2008; 14 Orimo ( key 20170425181757_aws055-B49) 2007; 113 Wakabayashi ( key 20170425181757_aws055-B63) 1998; 249 Eldrup ( key 20170425181757_aws055-B15) 1995; 92 Goldstein ( key 20170425181757_aws055-B71) 1989; 26 Goldstein ( key 20170425181757_aws055-B29) 2003; 2 Florang ( key 20170425181757_aws055-B18) 2007; 28 Arai ( key 20170425181757_aws055-B2) 2000; 296 Spillantini ( key 20170425181757_aws055-B61) 1997; 388 Werner ( key 20170425181757_aws055-B65) 2008; 6 Chia ( key 20170425181757_aws055-B5) 1993; 116 Ehringer ( key 20170425181757_aws055-B11) 1960; 38 Eisenhofer ( key 20170425181757_aws055-B12) 1986; 32 Goldstein ( key 20170425181757_aws055-B25) 2008; 18 Zarow ( key 20170425181757_aws055-B66) 2003; 60 Zhang ( key 20170425181757_aws055-B67) 2008; 129 Baraczka ( key 20170425181757_aws055-B3) 1983; 58 Gonzalez-Quevedo ( key 20170425181757_aws055-B31) 1993; 41 Orimo ( key 20170425181757_aws055-B51) 2001; 57 El-Agnaf ( key 20170425181757_aws055-B14) 2006; 20 Kaufmann ( key 20170425181757_aws055-B38) 2010; 74 Shi ( key 20170425181757_aws055-B58) 2011; 69 Ziegler ( key 20170425181757_aws055-B68) 1977; 296 Loeffler ( key 20170425181757_aws055-B46) 1995; 9 Raskind ( key 20170425181757_aws055-B56) 1999; 46 Kvetnansky ( key 20170425181757_aws055-B43) 1992; 58 Zweig ( key 20170425181757_aws055-B70) 1993; 43 Zubenko ( key 20170425181757_aws055-B69) 1986; 21 Shishido ( key 20170425181757_aws055-B59) 2010; 74 Velseboer ( key 20170425181757_aws055-B62) 2011; 17 Orimo ( key 20170425181757_aws055-B50) 2002; 73 Mandel ( key 20170425181757_aws055-B47) 2005; 1053 Freed ( key 20170425181757_aws055-B19) 1990; 2 2136056 - J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):114-5 21400565 - Ann Neurol. 2011 Mar;69(3):570-80 20157164 - Neurology. 2010 Feb 16;74(7):608-10 2510587 - Ann Neurol. 1989 Oct;26(4):558-63 21571570 - Parkinsonism Relat Disord. 2011 Dec;17(10):724-9 14502650 - Mov Disord. 2003 Sep;18 Suppl 6:S2-12 11109008 - Neurosci Lett. 2000 Dec 22;296(2-3):171-3 489 - J Pharmacol Exp Ther. 1975 Dec;195(3):453-64 18325818 - Parkinsonism Relat Disord. 2008 Dec;14(8):600-7 13658949 - Science. 1959 May 1;129(3357):1226-7 831126 - N Engl J Med. 1977 Feb 10;296(6):293-7 6420516 - J Neural Transm. 1983;58(3-4):299-304 8492957 - Neurology. 1993 May;43(5):986-91 1436520 - Neurology. 1992 Nov;42(11):2111-7 9029411 - J Neural Transm (Vienna). 1996;103(12):1441-5 3102548 - J Clin Endocrinol Metab. 1987 Apr;64(4):856-61 11971094 - Neurology. 2002 Apr 23;58(8):1247-55 18343778 - Am J Clin Pathol. 2008 Apr;129(4):526-9 20070850 - Ann Hum Genet. 2010 Mar;74(2):97-109 18695057 - Arch Neurol. 2008 Aug;65(8):1074-80 15317907 - Pharmacol Rev. 2004 Sep;56(3):331-49 16956664 - Neurotoxicology. 2007 Jan;28(1):76-82 1972319 - Ann Neurol. 1990 Apr;27(4):373-85 12438492 - J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):776-7 9448574 - Brain. 1997 Dec;120 ( Pt 12):2187-95 3096593 - Clin Chem. 1986 Nov;32(11):2030-3 6496118 - Acta Pharmacol Toxicol (Copenh). 1984 Aug;55(2):88-94 8205240 - J Chromatogr B Biomed Appl. 1994 Mar 4;653(2):131-8 13726012 - Klin Wochenschr. 1960 Dec 15;38:1236-9 19388687 - Chem Res Toxicol. 2009 May;22(5):835-41 16477495 - Clin Auton Res. 2006 Feb;16(1):46-54 7521168 - Bol Estud Med Biol. 1993 Jan-Dec;41(1-4):13-9 18363034 - Clin Auton Res. 2008 Apr;18(2):58-65 21785221 - J Clin Invest. 2011 Aug;121(8):3320-30 18079166 - Brain. 2008 Mar;131(Pt 3):642-50 8726100 - Clin Auton Res. 1996 Apr;6(2):125-6 6984110 - J Pharmacol Methods. 1982 Nov;8(3):183-96 16179542 - Ann N Y Acad Sci. 2005 Aug;1053:356-75 11823721 - J Cereb Blood Flow Metab. 2002 Feb;22(2):232-9 7605589 - J Neural Transm Park Dis Dement Sect. 1995;9(1):45-53 6721735 - Arch Neurol. 1984 Jun;41(6):612-4 17089131 - Acta Neuropathol. 2007 Jan;113(1):81-6 11571358 - Neurology. 2001 Sep 25;57(6):1140-1 3024746 - Biol Psychiatry. 1986 Dec;21(14):1365-81 20157156 - Neurology. 2010 Feb 16;74(7):536-7 12834252 - Neurochem Res. 2003 Aug;28(8):1145-50 12540289 - Clin Sci (Lond). 2003 Jun;104(6):649-54 12633144 - Arch Neurol. 2003 Mar;60(3):337-41 8336158 - J Neurol Sci. 1993 Jun;116(2):125-34 14678778 - Neurobiol Dis. 2003 Dec;14(3):637-47 18275612 - Proteome Sci. 2008 Feb 14;6:8 10494443 - Biol Psychiatry. 1999 Sep 15;46(6):756-65 7484057 - Acta Neurol Scand. 1995 Aug;92(2):116-21 16507759 - FASEB J. 2006 Mar;20(3):419-25 15338272 - Cell Tissue Res. 2004 Oct;318(1):121-34 1573408 - J Neurochem. 1992 Jun;58(6):2296-302 9278044 - Nature. 1997 Aug 28;388(6645):839-40 1913360 - Can J Neurol Sci. 1991 Aug;18(3):275-8 21317042 - Lancet Neurol. 2011 Mar;10(3):230-40 9682846 - Neurosci Lett. 1998 Jun 19;249(2-3):180-2 17455553 - Cleve Clin J Med. 2007 Feb;74 Suppl 1:S91-4 5171066 - JAMA. 1971 Dec 27;218(13):1903-8 1602395 - J Pharmacol Exp Ther. 1992 Jun;261(3):899-909 14572735 - Lancet Neurol. 2003 Nov;2(11):669-76 21073636 - Eur J Neurol. 2011 May;18(5):703-10 10517510 - Brain Pathol. 1999 Oct;9(4):721-32 9197268 - Science. 1997 Jun 27;276(5321):2045-7 19443601 - J Nucl Med. 2009 Jun;50(6):893-9 2445948 - J Pharm Pharmacol. 1987 Sep;39(9):705-10 8417011 - J Cereb Blood Flow Metab. 1993 Jan;13(1):57-69 |
| References_xml | – volume: 116 start-page: 125 year: 1993 ident: key 20170425181757_aws055-B6 article-title: Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease publication-title: J Neurol Sci doi: 10.1016/0022-510X(93)90316-Q – volume: 10 start-page: 230 year: 2011 ident: key 20170425181757_aws055-B48 article-title: alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70014-X – volume: 129 start-page: 526 year: 2008 ident: key 20170425181757_aws055-B67 article-title: CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases publication-title: Am J Clin Pathol doi: 10.1309/W01Y0B808EMEH12L – volume: 14 start-page: 637 year: 2003 ident: key 20170425181757_aws055-B20 article-title: ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2003.09.001 – volume: 296 start-page: 171 year: 2000 ident: key 20170425181757_aws055-B2 article-title: Pure autonomic failure in association with human alpha-synucleinopathy publication-title: Neurosci Lett doi: 10.1016/S0304-3940(00)01623-2 – volume: 27 start-page: 373 year: 1990 ident: key 20170425181757_aws055-B32 article-title: Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease publication-title: Ann Neurol doi: 10.1002/ana.410270405 – volume: 42 start-page: 2111 year: 1992 ident: key 20170425181757_aws055-B44 article-title: Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group publication-title: Neurology doi: 10.1212/WNL.42.11.2111 – volume: 18 start-page: 275 year: 1991 ident: key 20170425181757_aws055-B55 article-title: Accuracy of clinical diagnosis in parkinsonism–a prospective study publication-title: Can J Neurol Sci doi: 10.1017/S0317167100031814 – volume: 32 start-page: 2030 year: 1986 ident: key 20170425181757_aws055-B12 article-title: Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase publication-title: Clin Chem doi: 10.1093/clinchem/32.11.2030 – volume: 276 start-page: 2045 year: 1997 ident: key 20170425181757_aws055-B54 article-title: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease publication-title: Science doi: 10.1126/science.276.5321.2045 – volume: 8 start-page: 183 year: 1982 ident: key 20170425181757_aws055-B53 article-title: Value of monoamine metabolite determinations in CSF as an index of their concentrations in rat brain following various pharmacological manipulations publication-title: J Pharmacol Methods doi: 10.1016/0160-5402(82)90073-0 – volume: 41 start-page: 13 year: 1993 ident: key 20170425181757_aws055-B31 article-title: Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system publication-title: Bol Estud Med Biol – volume: 74 start-page: 536 year: 2010 ident: key 20170425181757_aws055-B38 article-title: Pure autonomic failure: a restricted Lewy body synucleinopathy or early Parkinson disease? publication-title: Neurology doi: 10.1212/WNL.0b013e3181d26982 – volume: 55 start-page: 88 year: 1984 ident: key 20170425181757_aws055-B57 article-title: Determination of conjugated dopamine in cerebrospinal fluid from humans and non-human primates with high performance liquid chromatography using electrochemical detection publication-title: Acta Pharmacol Toxicol doi: 10.1111/j.1600-0773.1984.tb01967.x – volume: 103 start-page: 1441 year: 1996 ident: key 20170425181757_aws055-B41 article-title: Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients publication-title: J Neural Transm doi: 10.1007/BF01271258 – volume: 22 start-page: 835 year: 2009 ident: key 20170425181757_aws055-B36 article-title: Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate publication-title: Chem Res Toxicol doi: 10.1021/tx800405v – volume: 18 start-page: 58 year: 2008 ident: key 20170425181757_aws055-B25 article-title: Central dopamine deficiency in pure autonomic failure publication-title: Clin Auton Res doi: 10.1007/s10286-008-0457-0 – volume: 41 start-page: 612 year: 1984 ident: key 20170425181757_aws055-B40 article-title: Cerebellar norepinephrine in patients with Parkinson's disease and control subjects publication-title: Arch Neurol doi: 10.1001/archneur.1984.04210080020007 – volume: 17 start-page: 724 year: 2011 ident: key 20170425181757_aws055-B62 article-title: Prevalence of orthostatic hypotension in Parkinson's disease: A systematic review and meta-analysis publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2011.04.016 – volume: 9 start-page: 45 year: 1995 ident: key 20170425181757_aws055-B46 article-title: Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid publication-title: J Neural Transm Park Dis Dement Sect doi: 10.1007/BF02252962 – volume: 65 start-page: 1074 year: 2008 ident: key 20170425181757_aws055-B8 article-title: Incidental Lewy body disease and preclinical Parkinson disease publication-title: Arch Neurol doi: 10.1001/archneur.65.8.1074 – volume: 18 start-page: S2 year: 2003 ident: key 20170425181757_aws055-B35 article-title: Neuropathological spectrum of synucleinopathies publication-title: Mov Disord doi: 10.1002/mds.10557 – volume: 46 start-page: 756 year: 1999 ident: key 20170425181757_aws055-B56 article-title: Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00008-6 – volume: 129 start-page: 1226 year: 1959 ident: key 20170425181757_aws055-B64 article-title: Blood-brain barrier for adrenaline publication-title: Science doi: 10.1126/science.129.3357.1226 – volume: 249 start-page: 180 year: 1998 ident: key 20170425181757_aws055-B63 article-title: Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy publication-title: Neurosci Lett doi: 10.1016/S0304-3940(98)00407-8 – volume: 74 start-page: 97 year: 2010 ident: key 20170425181757_aws055-B10 article-title: Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease publication-title: Ann Hum Genet doi: 10.1111/j.1469-1809.2009.00560.x – volume: 22 start-page: 232 year: 2002 ident: key 20170425181757_aws055-B60 article-title: Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data publication-title: J Cereb Blood Flow Metab doi: 10.1097/00004647-200202000-00011 – volume: 653 start-page: 131 year: 1994 ident: key 20170425181757_aws055-B33 article-title: Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection publication-title: J Chromatogr B Biomed Appl doi: 10.1016/0378-4347(93)E0430-X – volume: 38 start-page: 1236 year: 1960 ident: key 20170425181757_aws055-B11 article-title: [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.] publication-title: Wien Klin Wochenschr doi: 10.1007/BF01485901 – volume: 121 start-page: 3320 year: 2011 ident: key 20170425181757_aws055-B23 article-title: Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases publication-title: J Clin Inv doi: 10.1172/JCI45803 – volume: 261 start-page: 899 year: 1992 ident: key 20170425181757_aws055-B42 article-title: Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)11162-2 – volume: 50 start-page: 893 year: 2009 ident: key 20170425181757_aws055-B37 article-title: Simple ratio analysis of 18 F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls publication-title: J Nucl Med doi: 10.2967/jnumed.108.061572 – volume: 39 start-page: 705 year: 1987 ident: key 20170425181757_aws055-B16 article-title: Probenecid-induced accumulation of 5-hydroxyindoleacetic acid and homovanillic acid in rat brain publication-title: J Pharm Pharmacol doi: 10.1111/j.2042-7158.1987.tb06973.x – volume: 57 start-page: 1140 year: 2001 ident: key 20170425181757_aws055-B51 article-title: Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA publication-title: Neurology doi: 10.1212/WNL.57.6.1140 – volume: 2 start-page: 114 year: 1990 ident: key 20170425181757_aws055-B19 article-title: On the involvement of the locus ceruleus in Parkinson's disease publication-title: J Neuropsychiatry Clin Neurosci doi: 10.1176/jnp.2.1.114 – volume: 58 start-page: 2296 year: 1992 ident: key 20170425181757_aws055-B43 article-title: Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats publication-title: J Neurochem doi: 10.1111/j.1471-4159.1992.tb10977.x – volume: 104 start-page: 649 year: 2003 ident: key 20170425181757_aws055-B24 article-title: Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension publication-title: Clin Sci doi: 10.1042/CS20020315 – volume: 60 start-page: 337 year: 2003 ident: key 20170425181757_aws055-B66 article-title: Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases publication-title: Arch Neurol doi: 10.1001/archneur.60.3.337 – volume: 16 start-page: 46 year: 2006 ident: key 20170425181757_aws055-B30 article-title: Orthostatic hypotension as an early finding in Parkinson disease publication-title: Clin Auton Res doi: 10.1007/s10286-006-0317-8 – volume: 195 start-page: 453 year: 1975 ident: key 20170425181757_aws055-B45 article-title: The neurochemistry of Parkinson's disease: effect of L-dopa therapy publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)30363-0 – volume: 1053 start-page: 356 year: 2005 ident: key 20170425181757_aws055-B47 article-title: Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1344.031 – volume: 43 start-page: 986 year: 1993 ident: key 20170425181757_aws055-B70 article-title: The locus ceruleus and dementia in Parkinson's disease publication-title: Neurology doi: 10.1212/WNL.43.5.986 – volume: 116 start-page: 125 year: 1993 ident: key 20170425181757_aws055-B5 article-title: Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease publication-title: J Neurol Sci doi: 10.1016/0022-510X(93)90316-Q – volume: 74 start-page: S91 year: 2007 ident: key 20170425181757_aws055-B28 article-title: Cardiac denervation in patients with Parkinson disease publication-title: Cleve Clin J Med doi: 10.3949/ccjm.74.Suppl_1.S91 – volume: 28 start-page: 1145 year: 2003 ident: key 20170425181757_aws055-B17 article-title: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease publication-title: Neurochem Res doi: 10.1023/A:1024255208563 – volume: 13 start-page: 57 year: 1993 ident: key 20170425181757_aws055-B34 article-title: 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.1993.8 – volume: 74 start-page: 608 year: 2010 ident: key 20170425181757_aws055-B59 article-title: alpha-synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure publication-title: Neurology doi: 10.1212/WNL.0b013e3181cff6d5 – volume: 2 start-page: 669 year: 2003 ident: key 20170425181757_aws055-B29 article-title: Dysautonomia in Parkinson's disease: neurocardiological abnormalities publication-title: Lancet Neurol doi: 10.1016/S1474-4422(03)00555-6 – volume: 20 start-page: 419 year: 2006 ident: key 20170425181757_aws055-B14 article-title: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease publication-title: FASEB J doi: 10.1096/fj.03-1449com – volume: 28 start-page: 76 year: 2007 ident: key 20170425181757_aws055-B18 article-title: Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal publication-title: Neurotoxicology doi: 10.1016/j.neuro.2006.07.018 – volume: 318 start-page: 121 year: 2004 ident: key 20170425181757_aws055-B4 article-title: Stages in the development of Parkinson's disease-related pathology publication-title: Cell Tissue Res doi: 10.1007/s00441-004-0956-9 – volume: 131 start-page: 642 issue: Pt 3 year: 2008 ident: key 20170425181757_aws055-B52 article-title: Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease publication-title: Brain doi: 10.1093/brain/awm302 – volume: 73 start-page: 776 year: 2002 ident: key 20170425181757_aws055-B50 article-title: Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.73.6.776 – volume: 58 start-page: 1247 year: 2002 ident: key 20170425181757_aws055-B22 article-title: Orthostatic hypotension from sympathetic denervation in Parkinson’s disease publication-title: Neurology doi: 10.1212/WNL.58.8.1247 – volume: 296 start-page: 293 year: 1977 ident: key 20170425181757_aws055-B68 article-title: The sympathetic-nervous-system defect in primary orthostatic hypotension publication-title: N Engl J Med doi: 10.1056/NEJM197702102960601 – volume: 388 start-page: 839 year: 1997 ident: key 20170425181757_aws055-B61 article-title: Alpha-synuclein in Lewy bodies publication-title: Nature doi: 10.1038/42166 – volume: 6 start-page: 8 year: 2008 ident: key 20170425181757_aws055-B65 article-title: Proteome analysis of human substantia nigra in Parkinson's disease publication-title: Proteome Sci doi: 10.1186/1477-5956-6-8 – volume: 92 start-page: 116 year: 1995 ident: key 20170425181757_aws055-B15 article-title: CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.1995.tb01023.x – volume: 58 start-page: 299 year: 1983 ident: key 20170425181757_aws055-B3 article-title: Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration publication-title: J Neural Transm doi: 10.1007/BF01252815 – volume: 9 start-page: 721 year: 1999 ident: key 20170425181757_aws055-B9 article-title: Multiple system atrophy: a sporadic synucleinopathy publication-title: Brain Pathol doi: 10.1111/j.1750-3639.1999.tb00553.x – volume: 56 start-page: 331 year: 2004 ident: key 20170425181757_aws055-B13 article-title: Catecholamine metabolism: a contemporary view with implications for physiology and medicine publication-title: Pharmacol Rev doi: 10.1124/pr.56.3.1 – volume: 120 start-page: 2187 issue: Pt 12 year: 1997 ident: key 20170425181757_aws055-B1 article-title: Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease publication-title: Brain doi: 10.1093/brain/120.12.2187 – volume: 64 start-page: 856 year: 1987 ident: key 20170425181757_aws055-B27 article-title: Neuronal source of plasma dihydroxyphenylalanine publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem-64-4-856 – volume: 113 start-page: 81 year: 2007 ident: key 20170425181757_aws055-B49 article-title: Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy publication-title: Acta Neuropathol doi: 10.1007/s00401-006-0160-y – volume: 69 start-page: 570 year: 2011 ident: key 20170425181757_aws055-B58 article-title: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression publication-title: Ann Neurol doi: 10.1002/ana.22311 – volume: 6 start-page: 125 year: 1996 ident: key 20170425181757_aws055-B39 article-title: Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy publication-title: Clin Auton Res doi: 10.1007/BF02291236 – volume: 218 start-page: 1903 year: 1971 ident: key 20170425181757_aws055-B7 article-title: Levodopa in the treatment of Parkinsonism publication-title: JAMA doi: 10.1001/jama.1971.03190260019005 – volume: 26 start-page: 558 year: 1989 ident: key 20170425181757_aws055-B71 article-title: Patterns of plasma levels of catechols in neurogenic orthostatic hypotension publication-title: Ann Neurol doi: 10.1002/ana.410260410 – volume: 21 start-page: 1365 year: 1986 ident: key 20170425181757_aws055-B69 article-title: Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study publication-title: Biol Psychiatry doi: 10.1016/0006-3223(86)90328-8 – volume: 14 start-page: 600 year: 2008 ident: key 20170425181757_aws055-B21 article-title: Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2008.01.010 – volume: 18 start-page: 703 year: 2011 ident: key 20170425181757_aws055-B26 article-title: Catechols in post-mortem brain of patients with Parkinson disease publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.03246.x – reference: 21317042 - Lancet Neurol. 2011 Mar;10(3):230-40 – reference: 3102548 - J Clin Endocrinol Metab. 1987 Apr;64(4):856-61 – reference: 831126 - N Engl J Med. 1977 Feb 10;296(6):293-7 – reference: 1602395 - J Pharmacol Exp Ther. 1992 Jun;261(3):899-909 – reference: 5171066 - JAMA. 1971 Dec 27;218(13):1903-8 – reference: 21400565 - Ann Neurol. 2011 Mar;69(3):570-80 – reference: 11571358 - Neurology. 2001 Sep 25;57(6):1140-1 – reference: 18695057 - Arch Neurol. 2008 Aug;65(8):1074-80 – reference: 14678778 - Neurobiol Dis. 2003 Dec;14(3):637-47 – reference: 12834252 - Neurochem Res. 2003 Aug;28(8):1145-50 – reference: 19443601 - J Nucl Med. 2009 Jun;50(6):893-9 – reference: 8336158 - J Neurol Sci. 1993 Jun;116(2):125-34 – reference: 1913360 - Can J Neurol Sci. 1991 Aug;18(3):275-8 – reference: 19388687 - Chem Res Toxicol. 2009 May;22(5):835-41 – reference: 13726012 - Klin Wochenschr. 1960 Dec 15;38:1236-9 – reference: 2510587 - Ann Neurol. 1989 Oct;26(4):558-63 – reference: 2136056 - J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):114-5 – reference: 17455553 - Cleve Clin J Med. 2007 Feb;74 Suppl 1:S91-4 – reference: 10517510 - Brain Pathol. 1999 Oct;9(4):721-32 – reference: 8726100 - Clin Auton Res. 1996 Apr;6(2):125-6 – reference: 21785221 - J Clin Invest. 2011 Aug;121(8):3320-30 – reference: 2445948 - J Pharm Pharmacol. 1987 Sep;39(9):705-10 – reference: 6721735 - Arch Neurol. 1984 Jun;41(6):612-4 – reference: 9448574 - Brain. 1997 Dec;120 ( Pt 12):2187-95 – reference: 10494443 - Biol Psychiatry. 1999 Sep 15;46(6):756-65 – reference: 9278044 - Nature. 1997 Aug 28;388(6645):839-40 – reference: 489 - J Pharmacol Exp Ther. 1975 Dec;195(3):453-64 – reference: 20070850 - Ann Hum Genet. 2010 Mar;74(2):97-109 – reference: 7484057 - Acta Neurol Scand. 1995 Aug;92(2):116-21 – reference: 14572735 - Lancet Neurol. 2003 Nov;2(11):669-76 – reference: 1436520 - Neurology. 1992 Nov;42(11):2111-7 – reference: 18275612 - Proteome Sci. 2008 Feb 14;6:8 – reference: 16956664 - Neurotoxicology. 2007 Jan;28(1):76-82 – reference: 1972319 - Ann Neurol. 1990 Apr;27(4):373-85 – reference: 18363034 - Clin Auton Res. 2008 Apr;18(2):58-65 – reference: 8205240 - J Chromatogr B Biomed Appl. 1994 Mar 4;653(2):131-8 – reference: 21571570 - Parkinsonism Relat Disord. 2011 Dec;17(10):724-9 – reference: 8492957 - Neurology. 1993 May;43(5):986-91 – reference: 16179542 - Ann N Y Acad Sci. 2005 Aug;1053:356-75 – reference: 6984110 - J Pharmacol Methods. 1982 Nov;8(3):183-96 – reference: 3096593 - Clin Chem. 1986 Nov;32(11):2030-3 – reference: 11823721 - J Cereb Blood Flow Metab. 2002 Feb;22(2):232-9 – reference: 11109008 - Neurosci Lett. 2000 Dec 22;296(2-3):171-3 – reference: 3024746 - Biol Psychiatry. 1986 Dec;21(14):1365-81 – reference: 20157156 - Neurology. 2010 Feb 16;74(7):536-7 – reference: 12633144 - Arch Neurol. 2003 Mar;60(3):337-41 – reference: 21073636 - Eur J Neurol. 2011 May;18(5):703-10 – reference: 15317907 - Pharmacol Rev. 2004 Sep;56(3):331-49 – reference: 6496118 - Acta Pharmacol Toxicol (Copenh). 1984 Aug;55(2):88-94 – reference: 9682846 - Neurosci Lett. 1998 Jun 19;249(2-3):180-2 – reference: 14502650 - Mov Disord. 2003 Sep;18 Suppl 6:S2-12 – reference: 13658949 - Science. 1959 May 1;129(3357):1226-7 – reference: 18325818 - Parkinsonism Relat Disord. 2008 Dec;14(8):600-7 – reference: 9029411 - J Neural Transm (Vienna). 1996;103(12):1441-5 – reference: 11971094 - Neurology. 2002 Apr 23;58(8):1247-55 – reference: 12438492 - J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):776-7 – reference: 9197268 - Science. 1997 Jun 27;276(5321):2045-7 – reference: 17089131 - Acta Neuropathol. 2007 Jan;113(1):81-6 – reference: 20157164 - Neurology. 2010 Feb 16;74(7):608-10 – reference: 18079166 - Brain. 2008 Mar;131(Pt 3):642-50 – reference: 15338272 - Cell Tissue Res. 2004 Oct;318(1):121-34 – reference: 7605589 - J Neural Transm Park Dis Dement Sect. 1995;9(1):45-53 – reference: 6420516 - J Neural Transm. 1983;58(3-4):299-304 – reference: 16477495 - Clin Auton Res. 2006 Feb;16(1):46-54 – reference: 7521168 - Bol Estud Med Biol. 1993 Jan-Dec;41(1-4):13-9 – reference: 18343778 - Am J Clin Pathol. 2008 Apr;129(4):526-9 – reference: 1573408 - J Neurochem. 1992 Jun;58(6):2296-302 – reference: 16507759 - FASEB J. 2006 Mar;20(3):419-25 – reference: 8417011 - J Cereb Blood Flow Metab. 1993 Jan;13(1):57-69 – reference: 12540289 - Clin Sci (Lond). 2003 Jun;104(6):649-54 |
| SSID | ssj0014326 |
| Score | 2.415181 |
| Snippet | Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of neuronal... Central catecholamine deficiency characterizes alpha -synucleinopathies such as Parkinson's disease. We hypothesized that cerebrospinal fluid levels of... Central catecholamine deficiency characterizes α-synucleinopathies such as Parkinson’s disease. We hypothesized that cerebrospinal fluid levels of neuronal... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1900 |
| SubjectTerms | 3,4-Dihydroxyphenylacetic Acid - cerebrospinal fluid Aged Biological and medical sciences Biomarkers - blood Biomarkers - cerebrospinal fluid Catecholamines - blood Catecholamines - cerebrospinal fluid Catecholamines - deficiency Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dopamine Agents - therapeutic use Female Fluorodeoxyglucose F18 Follow-Up Studies Humans Levodopa - therapeutic use Male Medical sciences Methoxyhydroxyphenylglycol - analogs & derivatives Methoxyhydroxyphenylglycol - blood Methoxyhydroxyphenylglycol - cerebrospinal fluid Middle Aged Multiple System Atrophy - blood Multiple System Atrophy - cerebrospinal fluid Multiple System Atrophy - diagnostic imaging Multiple System Atrophy - drug therapy Neurology Original Parkinsonian Disorders - cerebrospinal fluid Parkinsonian Disorders - diagnostic imaging Parkinsonian Disorders - drug therapy Positron-Emission Tomography Pure Autonomic Failure - blood Pure Autonomic Failure - cerebrospinal fluid Pure Autonomic Failure - diagnostic imaging Pure Autonomic Failure - drug therapy ROC Curve |
| Title | Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22451506 https://www.proquest.com/docview/1016676315 https://www.proquest.com/docview/1434016993 https://pubmed.ncbi.nlm.nih.gov/PMC3359749 |
| Volume | 135 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2Mwxq5ddikabOyheHUsWZIfsy5dsjUtrCn0LVi2TA2tU-KEwf7J_u2OLlHsLt3txSSOsEzOJ-mco0_fQeiNVn9UWaoCMDgJYCRmgWBSBZIViYyoKphRYhofseEp_XwWn3U6PxqspeVCvs--bzxX8j9WhXtgV31K9h8s6x8KN-Az2BeuYGG4_pWN99UcQlpd-UP7lMXFsgR3spxdasrN3HA0HPdyV_OeTBh7qb3KXGndCHPosoQ5MNX5ckMK4fVqx8ZsKpjTWVrUQIsel9XMlC92pEMvipSW1ca6IDbZILhoJBs-HR9-PJkMRkeeTr9OvQ6PD8cDQyTUdfQWlfLJ_pNh_2v_w8isFupcp_sdpF22QtM-WDNbccMpyNYMzQKRWDFaP0OTuDHHggsTNtZrCDjJxrXA6mTJucmwHKTf6tAKArdFt68thp6iCGFhD1xTdgvdjiACMdH66IvfoKLEVPLzr-vOVECfe6bHPdtfy9u5d5XWMPAKWzFlU0hznZnbcHUmD9B9F6PgvgXcQ9RR1SN0Z-xYGI_RsoU7bHCH17jDswK7J-MW7vAad7issMfduxo71GHADTaow7-g7gk6PRhM9oeBK98RZDDuF0GSExr1VCKIDDknMs_DWIicx5IwWkRKCviWJlEuUq2jx4skzDm454rHMeE5I0_RVjWr1DOEJaw0BWV5xmJFKacQ04RpKsJECsIz1eui3dXfPM2ctr0usXIxtRwLMjVGmVqjdNFb3_rKarrc0G6nZTHfeIWNLnq9MuEUZmW91ZZWarasDXGSwdLdi3_ThhKqtZAS0kXb1uzrHiIaa-3PLuItQPgGWhW-_UtVnht1eEJ0jiB5_qeXf4HurgfoS7S1mC_VK3CwF3LHQP0nN-nYyQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cerebrospinal+fluid+biomarkers+of+central+catecholamine+deficiency+in+Parkinson%27s+disease+and+other+synucleinopathies&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=GOLDSTEIN%2C+David+S&rft.au=HOLMES%2C+Courtney&rft.au=SHARABI%2C+Yehonatan&rft.date=2012-06-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.volume=135&rft.spage=1900&rft.epage=1913&rft_id=info:doi/10.1093%2Fbrain%2Faws055&rft.externalDBID=n%2Fa&rft.externalDocID=25912266 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon |